How do Mesoblast’s proprietary Mesenchymal Precursor Cells (MPCs) reduce damaging inflammation and reverse endothelial dysfunction?
Mesoblast’s preclinical studies have shown that MPCs secrete specific factors which convert the pro-inflammatory M1 macrophage to an anti-inflammatory M2 macrophage (a phenomenon termed
macrophage polarization). This results in switching off the production of damaging inflammatory factors.
Cell Therapy News/Articles, page-249
-
- There are more pages in this discussion • 17,537 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |